To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves two drugs for first-line AML

FDA approved on Nov. 28 two drugs for first-line treatment of acute myelogenous leukemia, setting off a race in a setting that's been void of new approvals for patients who do not harbor an FMS-like tyrosine kinase 3 (FLT3; CD135) or isocitrate dehydrogenase 1 (IDH1) mutation. The agency also accepted for Priority Review an NDA

Read the full 559 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers